CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 déc. 2024 16h05 HE
|
CG Oncology Inc.
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Comprehensive Epidemiology Forecast Reveals Significant Insights into Prader-Willi Syndrome Through 2034
02 déc. 2024 04h42 HE
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.Demographics and...
10 year 8 Major Market Bladder Cancer Epidemiology Forecasts 2023-2033
18 nov. 2024 10h20 HE
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.Bladder cancer (International Classification...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
14 oct. 2024 10h30 HE
|
Biofrontera Inc.
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of malignant lesions.Data now being analyzed, interim...
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 août 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
12 août 2024 08h30 HE
|
Atossa Therapeutics, Inc.
Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual...
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08 août 2024 08h23 HE
|
CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
18 juin 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec